BMC Cancer · 2013 · 16 citations · 18 references
MedicineOncologyRadiation OncologyDiagnostic ImagingRadiation DosimetryTreatment PlanningRadiation TherapyRadiation Treatment PlanningRenal ImagingRenal Nuclear ImagingRenal ScintigraphyResponse AssessmentGlomerular Filtration Rate MeasurementKidney DosimetryKidney Function MonitoringRadiation Dose AssessmentRadiation Response AssessmentRadiotherapy Dose PlanningRenal Function EvaluationRenal Nuclear Scintigraphy
The kidneys are a principal dose-limiting organ in radiotherapy for upper abdominal cancers. The current understanding of kidney radiation dose response is rudimentary. More precise dose-volume response models that allow direct correlation of delivered radiation dose with spatio-temporal changes in kidney function may improve radiotherapy treatment planning for upper-abdominal tumours. Our current understanding of kidney dose response and tolerance is limited and this is hindering efforts to introduce advanced radiotherapy techniques for upper-abdominal cancers, such as intensity-modulated radiotherapy (IMRT). The aim of this study is to utilise radiotherapy and combined anatomical/functional imaging data to allow direct correlation of radiation dose with spatio-temporal changes in kidney function. The data can then be used to develop a more precise dose-volume response model which has the potential to optimise and individualise upper abdominal radiotherapy plans. The Radiotherapy of Abdomen with Precise Renal Assessment with SPECT/CT Imaging (RAPRASI) is an observational clinical research study with participating sites at Sir Charles Gairdner Hospital (SCGH) in Perth, Australia and the Peter MacCallum Cancer Centre (PMCC) in Melbourne, Australia. Eligible patients are those with upper gastrointestinal cancer, without metastatic disease, undergoing conformal radiotherapy that will involve incidental radiation to one or both kidneys. For each patient, total kidney function is being assessed before commencement of radiotherapy treatment and then at 4, 12, 26, 52 and 78 weeks after the first radiotherapy fraction, using two procedures: a Glomerular Filtration Rate (GFR) measurement using the 51Cr-ethylenediamine tetra-acetic acid (EDTA) clearance; and a regional kidney perfusion measurement assessing renal uptake of 99mTc-dimercaptosuccinic acid (DMSA), imaged with a Single Photon Emission Computed Tomography / Computed Tomography (SPECT/CT) system. The CT component of the SPECT/CT provides the anatomical reference of the kidney’s position. The data is intended to reveal changes in regional kidney function over the study period after the radiotherapy. These SPECT/CT scans, co-registered with the radiotherapy treatment plan, will provide spatial correlation between the radiation dose and regional renal function as assessed by SPECT/CT. From this correlation, renal response patterns will likely be identified with the purpose of developing a predictive model. Australian New Zealand Clinical Trials Registry: ACTRN12609000322235
18
Tolerance of Normal Tissue to Therapeutic Radiation
Bahman Emami · Reports of Radiotherapy and Oncology · 2013 · 456 citations
Use of the BrainLAB ExacTrac X-Ray 6D System in Image-Guided Radiotherapy
Jian‐Yue Jin, F Yin, Stephen Tenn et al. · Medical dosimetry · 2008 · 208 citations